Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18984687 | 0.77 | PNP (0.51) | PNPKMT2AMEN1ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL8846302 | 0.76 | PNP (0.50) | PNPKMT2AMEN1ALDH1A1HSD17B10 | |
| 8-Aminoguanine SCHEMBL21761 | 0.73 | PNP (1.00) | PNPKMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL11679829 | 0.72 | TSHR (0.54) | KMT2AMEN1POLBPIM1TSHR | |
| SCHEMBL11680654 | 0.72 | MEN1 (0.53) | KMT2AMEN1POLBTSHRALDH1A1 | |
| SCHEMBL2776067 | 0.70 | NUDT1 (0.46) | KMT2AMEN1POLBXDHMAPT | |
| SCHEMBL10309260 | 0.70 | GAA (0.58) | KMT2AMEN1PIM1TSHRALDH1A1 | |
| SCHEMBL31368010 | 0.68 | MAPT (0.67) | KMT2AMEN1POLBPIM1TSHR | |
| SCHEMBL10597942 | 0.67 | PNP (0.70) | PNPKMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL13217389 | 0.67 | KMT2A (0.47) | KMT2AMEN1POLBPIM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| CN-101861318-A | Method of synthesis of morpholino oligomers | AVI BIOPHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| CN-101861318-A | Method of synthesis of morpholino oligomers | AVI BIOPHARMA INC | 2010-10-13 | — | — | CN | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | RNMT, O60361, PAM | PNP 361/4885KMT2A 1164/4885MEN1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.